Comprehensive 2026 outlook on U.S. healthcare and insurance sector covering AI adoption, Medicare Advantage growth, pharmaceutical scrutiny, market consolidations, and emerging health equity focus.
New Medicare drug price negotiations reduce government costs on 15 high-spend medications, including cancer and diabetes treatments, saving $12 billion annually.
The Trump administration finalizes agreements reducing Medicare prices for 15 drugs, aiming to save billions and impact Medicare Part D plans and drug affordability policies.
Pharmaceutical companies agree to significant Medicare drug price cuts under Trump administration, projecting billions in savings with impacts on Medicare Part D and drug affordability.
CMS unveils the GENERous Medicaid payment model introducing MFN drug pricing, alongside expanded Trump administration drug pricing agreements and key regulatory updates for 2026.
Novo Nordisk and Eli Lilly agree to lower GLP-1 drug prices in exchange for expanded Medicare and Medicaid coverage, marking a major shift in U.S. drug pricing and access.
The looming deadline for drugmakers to comply with the Most Favored Nation drug pricing policy raises concerns over potential disruptions to Medicare Part D, highlighting regulatory and market risks for U.S. drug pricing and federal entitlement programs.
Analysis finds GLP-1 drugs like semaglutide offer real health benefits but raise insurance coverage and cost challenges amid growing demand in the U.S. market.
FTC cautions healthcare employers on noncompetes. Rising physician unionization, Medicare Plan Finder updates, Kaiser-Renown joint venture, AI tools, FDA drug approvals, and robotic intubation device mark key healthcare industry trends in 2025.
Delaware Department of Insurance analysis finds GLP-1 drug prices effectively stable after rebates, indicating limited impact on health insurance cost increases despite higher utilization.
